HIV-1 Integrase-DNA Models

HIV-1 Integrase: Mechanism and Inhibitor Design

Volumn , Issue , 2011, Pages 429-455

  Liao, Chenzhong ^a   Nicklaus, Marc C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Anti HIV drugs, IN inhibition; EM 3D map; HIV 1 integrase DNA models

Indexed keywords

EID: 84884976988     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118015377.ch28     Document Type: Chapter

References (114)

1. Neamati, N. Structure-based HIV-1 integrase inhibitor design: A future perspective. Expert Opin. Investig. Drugs 2001, 10, 281-296.
2. Chen, I. J.; Neamati, N.; MacKerell, A. D., Jr. Structurebased inhibitor design targeting HIV-1 integrase. Curr. Drug Targets Infect. Disord. 2002, 2, 217-234.
3. Pommier, Y.; Johnson, A. A.; Marchand, C. Integrase inhibitors to treat HIV/AIDS. Nat. Rev. Drug Discov. 2005, 4, 236-248.
4. Castro, H. C.; Loureiro, N. I.; Pujol-Luz, M.; Souza, A. M.; Albuquerque, M. G.; Santos, D. O.; Cabral, L. M.; Frugulhetti, I. C.; Rodrigues, C. R. HIV-1 reverse transcriptase: A therapeutical target in the spotlight. Curr. Med. Chem. 2006, 13, 313-324.
5. Louis, J. M.; Ishima, R.; Torchia, D. A.; Weber, I. T. HIV-1 protease: Structure, dynamics, and inhibition. Adv. Pharmacol. 2007, 55, 261-298.
6. Hare, S.; Gupta, S. S.; Valkov, E.; Engelman, A.; Cherepanov, P. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature. 2010, 464, 232-236.
7. Cai, M.; Zheng, R.; Caffrey, M.; Craigie, R.; Clore, G. M.; Gronenborn, A. M. Solution structure of the N-terminal zinc binding domain of HIV-1 integrase. Nat. Struct. Biol. 1997, 4, 567-577.
8. Wang, J. Y.; Ling, H.; Yang, W.; Craigie, R. Structure of a two-domain fragment of HIV-1 integrase: Implications for domain organization in the intact protein. EMBO J. 2001, 20, 7333-7343.
9. Chen, J. C.; Krucinski, J.; Miercke, L. J.; Finer-Moore, J. S.; Tang, A. H.; Leavitt, A. D.; Stroud, R. M. Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: A model for viral DNA binding. Proc. Natl. Acad. Sci. USA 2000, 97, 8233-8238.
10. Chen, Z.; Yan, Y.; Munshi, S.; Li, Y.; Zugay-Murphy, J.; Xu, B.; Witmer, M.; Felock, P.; Wolfe, A.; Sardana, V.; Emini, E. A.; Hazuda, D.; Kuo, L. C. X-ray structure of simian immunodeficiency virus integrase containing the core and C-terminal domain (residues 50-293)-An initial glance of the viral DNA binding platform. J. Mol. Biol. 2000, 296, 521-533.
11. Yang, Z. N.; Mueser, T. C.; Bushman, F. D.; Hyde, C. C. Crystal structure of an active two-domain derivative of Rous sarcoma virus integrase. J. Mol. Biol. 2000, 296, 535-548.
12. Goldgur, Y.; Dyda, F.; Hickman, A. B.; Jenkins, T. M.; Craigie, R.; Davies, D. R. Three new structures of the core domain of HIV-1 integrase: An active site that binds magnesium. Proc. Natl. Acad. Sci. USA 1998, 95, 9150-9154.
13. Bujacz, G.; Alexandratos, J.; Qing, Z. L.; Clement-Mella, C.; Wlodawer, A. The catalytic domain of human immunodeficiency virus integrase: Ordered active site in the F185H mutant. FEBS Lett. 1996, 398, 175-178.
14. Dyda, F.; Hickman, A. B.; Jenkins, T. M.; Engelman, A.; Craigie, R.; Davies, D. R. Crystal structure of the catalytic domain of HIV-1 integrase: Similarity to other polynucleotidyl transferases. Science 1994, 266, 1981-1986.
15. Maignan, S.; Guilloteau, J. P.; Zhou-Liu, Q.; Clement-Mella, C.; Mikol, V. Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: High level of similarity of the active site with other viral integrases. J. Mol. Biol. 1998, 282, 359-368.
16. Goldgur, Y.; Craigie, R.; Cohen, G. H.; Fujiwara, T.; Yoshinaga, T.; Fujishita, T.; Sugimoto, H.; Endo, T.; Murai, H.; Davies, D. R. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: A platform for antiviral drug design. Proc. Natl. Acad. Sci. USA 1999, 96, 13040-13043.
17. Hazuda, D. J.; Felock, P.; Witmer, M.; Wolfe, A.; Stillmock, K.; Grobler, J. A.; Espeseth, A.; Gabryelski, L.; Schleif, W.; Blau, C.; Miller, M. D. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000, 287, 646-650.
18. Leh, H.; Brodin, P.; Bischerour, J.; Deprez, E.; Tauc, P.; Brochon, J. C.; LeCam, E.; Coulaud, D.; Auclair, C.; Mouscadet, J. F. Determinants of Mg2{thorn} -dependent activities of recombinant human immunodeficiency virus type 1 integrase. Biochemistry 2000, 39, 9285-9294.
19. Neamati, N.; Lin, Z.; Karki, R. G.; Orr, A.; Cowansage, K.; Strumberg, D.; Pais, G. C.; Voigt, J. H.; Nicklaus, M. C.; Winslow, H. E.; Zhao, H.; Turpin, J. A.; Yi, J.; Skalka, A. M.; Burke, T. R., Jr.; Pommier, Y. Metal-dependent inhibition of HIV-1 integrase. J. Med. Chem. 2002, 45, 5661-5670.
20. Marchand, C.; Johnson, A. A.; Karki, R. G.; Pais, G. C.; Zhang, X.; Cowansage, K.; Patel, T. A.; Nicklaus, M. C.; Burke, T. R., Jr.; Pommier, Y. Metal-dependent inhibition of HIV-1 integrase by beta-diketo acids and resistance of the soluble double-mutant (F185K/C280S). Mol. Pharmacol. 2003, 64, 600-609.
21. Davies, D. R.; Goryshin, I. Y.; Reznikoff, W. S.; Rayment, I. Three-dimensional structure of the Tn5 synaptic complex transposition intermediate. Science 2000, 289, 77-85.
22. Aishima, J.; Gitti, R. K.; Noah, J. E.; Gan, H. H.; Schlick, T.; Wolberger, C. A Hoogsteen base pair embedded in undistorted B-DNA. Nucleic Acids Res. 2002, 30, 5244-5252.
23. Norman, D. P.; Bruner, S. D.; Verdine, G. L. Coupling of substrate recognition and catalysis by a human base-excision DNA repair protein. J. Am. Chem. Soc. 2001, 123, 359-360.
24. Chen, A.;Weber, I. T.; Harrison, R.W.; Leis, J. Identification of amino acids in HIV-1 and avian sarcoma virus integrase subsites required for specific recognition of the long terminal repeat ends. J. Biol. Chem. 2006, 281, 4173-4182.
25. Lins, R. D.; Briggs, J. M.; Straatsma, T. P.; Carlson, H. A.; Greenwald, J.; Choe, S.; McCammon, J. A. Molecular dynamics studies on the HIV-1 integrase catalytic domain. Biophys. J. 1999, 76, 2999-3011.
26. Lins, R. D.; Adesokan, A.; Soares, T. A.; Briggs, J. M. Investigations on human immunodeficiency virus type 1 integrase/DNA binding interactions via molecular dynamics and electrostatics calculations. Pharmacol. Ther. 2000, 85, 123-131.
27. Ni, H.; Sotriffer, C. A.; McCammon, J. A. Ordered water and ligand mobility in the HIV-1 integrase-5CITEP complex: A molecular dynamics study. J. Med. Chem. 2001, 44, 3043-3047.
28. Barreca, M. L.; Lee, K. W.; Chimirri, A.; Briggs, J. M. Molecular dynamics studies of the wild-type and double mutant HIV-1 integrase complexed with the 5CITEP inhibitor: Mechanism for inhibition and drug resistance. Biophys. J. 2003, 84, 1450-1463.
29. Brigo, A.; Lee, K.W.; Iurcu Mustata, G.; Briggs, J. M. Comparison of multiple molecular dynamics trajectories calculated for the drug-resistant HIV-1 integrase T66I/ M154I catalytic domain. Biophys. J. 2005, 88, 3072-3082.
30. Brigo, A.; Lee, K. W.; Fogolari, F.; Mustata, G. I.; Briggs, J. M. Comparative molecular dynamics simulations of HIV-1 integrase and the T66I/M154I mutant: Binding modes and drug resistance to a diketo acid inhibitor. Proteins 2005, 59, 723-741.
31. Lee, M. C.; Deng, J.; Briggs, J. M.; Duan, Y. Large-scale conformational dynamics of the HIV-1 integrase core domainand its catalytic loop mutants. Biophys. J. 2005, 88, 3133-3146.
32. Sotriffer, C. A.; Ni, H.; McCammon, J. A. HIV-1 integrase inhibitor interactions at the active site: Prediction of binding modes unaffected by crystal packing. J. Am. Chem. Soc. 2000, 122, 6136-6137.
33. Sotriffer, C. A.; Ni, H.; McCammon, J. A. Active site binding modes of HIV-1 integrase inhibitors. J. Med. Chem. 2000, 43, 4109-4117.
34. Keseru, G. M.; Kolossvary, I. Fully flexible low-mode docking: Application to induced fit in HIVintegrase. J. Am. Chem. Soc. 2001, 123, 12708-12709.
35. Dayam, R.; Neamati, N. Active site binding modes of the beta-diketoacids: A multi-active site approach in HIV-1 integrase inhibitor design. Bioorg. Med. Chem. 2004, 12, 6371-6381.
36. Cox, A. G.; Nair, V. Novel HIV integrase inhibitors with anti-HIV activity: Insights into integrase inhibition from docking studies. Antivir. Chem. Chemother. 2006, 17, 343-353.
37. Perryman, A. L.; McCammon, J. A. AutoDocking dinucleotides to the HIV-1 integrase core domain: Exploring possible binding sites for viral and genomic DNA. J. Med. Chem. 2002, 45, 5624-5627.
38. Adesokan, A. A.; Roberts, V. A.; Lee, K. W.; Lins, R. D.; Briggs, J. M. Prediction of HIV-1 integrase/viral DNA interactions in the catalytic domain by fast molecular docking. J. Med. Chem. 2004, 47, 821-828.
39. Chiu, T. K.; Davies, D. R. Structure and function of HIV-1 integrase. Curr. Top. Med. Chem. 2004, 4, 965-977.
40. Agapkina, J.; Smolov, M.; Barbe, S.; Zubin, E.; Zatsepin, T.; Deprez, E.; Le Bret, M.; Mouscadet, J. F.; Gottikh, M. Probing of HIV-1 integrase/DNA interactions using novel analogs of viral DNA. J. Biol. Chem. 2006, 281, 11530-11540.
41. Savarino, A. In-silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate. Retrovirology 2007, 4, 21-34.
42. Nunthaboot, N.; Pianwanit, S.; Parasuk,V.;Kokpol, S.; Briggs, J. M. Computational studies of HIV-1 integrase and its inhibitors. Curr. Comput-Aided Drug Des. 2007, 3, 160-190.
43. Chen, X.; Tsiang, M.; Yu, F.; Hung, M.; Jones, G. S.; Zeynalzadegan, A.; Qi, X.; Jin, H.; Kim, C. U.; Swaminathan, S.; Chen, J. M. Modeling, analysis, and validation of a novel HIV integrase structure provide insights into the binding modes of potent integrase inhibitors. J. Mol. Biol. 2008, 380, 504-519.
44. Barreca, M. L.; Iraci, N.; De Luca, L.; Chimirri, A. Inducedfit docking approach provides insight into the binding mode and mechanism of action of HIV-1 integrase inhibitors. ChemMedChem 2009, 4, 1446-1456.
45. Liao, C.; Nicklaus, M. C. Computer tools in the discovery of HIV-1 integrase inhibitors. Future Med Chem, 2010, 2, 1123-1140.
46. Fenollar-Ferrer, C.; Carnevale, V.; Raugei, S.; Carloni, P. HIV-1 integrase-DNA interactions investigated by molecular modelling. Comput. Math Methods Med. 2008, 9, 231-243.
47. Heuer, T. S.; Brown, P. O. Photo-cross-linking studies suggest a model for the architecture of an active human immunodeficiency virus type 1 integrase-DNA complex. Biochemistry 1998, 37, 6667-6678.
48. Heuer, T. S.; Brown, P. O. Mapping features of HIV-1 integrase near selected sites on viral and target DNA molecules in an active enzyme-DNA complex by photocross-linking. Biochemistry 1997, 36, 10655-10665.
49. Gao, Y. G.; Su, S. Y.; Robinson, H.; Padmanabhan, S.; Lim, L.; McCrary, B. S.; Edmondson, S. P.; Shriver, J. W.; Wang, A. H. The crystal structure of the hyperthermophile chromosomal protein Sso7d bound to DNA. Nat. Struct. Biol. 1998, 5, 782-786.
50. Robinson, H.; Gao, Y. G.; McCrary, B. S.; Edmondson, S. P.; Shriver, J. W.; Wang, A. H. The hyperthermophile chromosomal protein Sac7d sharply kinks DNA. Nature 1998, 392, 202-205.
51. Krueger, J. K.; McCrary, B. S.; Wang, A. H.; Shriver, J. W.; Trewhella, J.; Edmondson, S. P. The solution structure of the Sac7d/DNA complex: A small-angle X-ray scattering study. Biochemistry 1999, 38, 10247-10255.
52. Ferrin, T. E.; Huang, C. C.; Jarvis, L. E.; Langridge, R. The MIDAS display system. J. Mol. Graphics 1988, 6, 13-27.
53. Gao, K.; Butler, S. L.; Bushman, F. Human immunodeficiency virus type 1 integrase: Arrangement of protein domains in active cDNA complexes. EMBO J. 2001, 20, 3565-3576.
54. Podtelezhnikov, A. A.; Gao, K.; Bushman, F. D.; McCammon, J. A. Modeling HIV-1 integrase complexes based on their hydrodynamic properties. Biopolymers 2003, 68, 110-120.
55. Deprez, E.; Tauc, P.; Leh, H.; Mouscadet, J. F.; Auclair, C.; Brochon, J. C. Oligomeric states of the HIV-1 integrase as measured by time-resolved fluorescence anisotropy. Biochemistry 2000, 39, 9275-9284.
56. Rice, P. A.; Baker, T. A. Comparative architecture of transposase and integrase complexes. Nat. Struct. Biol. 2001, 8, 302-307.
57. Di Santo, R.; Costi, R.; Roux, A.; Artico, M.; Lavecchia, A.; Marinelli, L.; Novellino, E.; Palmisano, L.; Andreotti, M.; Amici, R.; Galluzzo, C. M.; Nencioni, L.; Palamara, A. T.; Pommier, Y.; Marchand, C. Novel bifunctional quinolonyl diketo acid derivatives as HIV-1 integrase inhibitors: Design, synthesis, biological activities, and mechanism of action. J. Med. Chem. 2006, 49, 1939-1945.
58. De Luca, L.; Pedretti, A.; Vistoli, G.; Barreca, M. L.; Villa, L.; Monforte, P.; Chimirri, A. Analysis of the full-length integrase-DNA complex by a modified approach for DNA docking. Biochem. Biophys. Res. Commun. 2003, 310, 1083-1088.
59. Ausiello, G.; Cesareni, G.; Helmer-Citterich, M. ESCHER: A new docking procedure applied to the reconstruction of protein tertiary structure. Proteins 1997, 28, 556-567.
60. De Luca, L.; Vistoli, G.; Pedretti, A.; Barreca, M. L.; Chimirri, A. Molecular dynamics studies of the full-length integrase-DNA complex. Biochem. Biophys. Res. Commun. 2005, 336, 1010-1016.61
61. Karki, R. G.; Tang, Y.; Burke, T. R., Jr.; Nicklaus, M. C. Model of full-length HIV-1 integrase complexed with viral DNA as template for anti-HIV drug design. J. Comput. Aided Mol. Des. 2004, 18, 739-760.
62. Zhang, X.; Pais, G. C.; Svarovskaia, E. S.; Marchand, C.; Johnson, A. A.; Karki, R. G.; Nicklaus, M. C.; Pathak, V. K.; Pommier, Y.; Burke, T. R. Azido-containing aryl beta-diketo acid HIV-1 integrase inhibitors. Bioorg. Med. Chem. Lett. 2003, 13, 1215-1219.
63. Liao, C.; Karki, R. G.; Marchand, C.; Pommier, Y.; Nicklaus, M. C. Virtual screening application of a model of full-length HIV-1 integrase complexed with viral DNA. Bioorg. Med. Chem. Lett. 2007, 17, 5361-5365.
64. Wielens, J.; Crosby, I. T.; Chalmers, D. K. A threedimensional model of the human immunodeficiency virus type 1 integration complex. J. Comput. Aided Mol. Des. 2005, 19, 301-317.
65. Jenkins, T. M.; Esposito, D.; Engelman, A.; Craigie, R. Critical contacts between HIV-1 integrase and viral DNA identified by structure-based analysis and photo-crosslinking. EMBO J. 1997, 16, 6849-6859.
66. Esposito, D.; Craigie, R. Sequence specificity of viral end DNA binding by HIV-1 integrase reveals critical regions for protein-DNA interaction. EMBO J. 1998, 17, 5832-5843.
67. Pryciak, P. M.; Varmus, H. E. Nucleosomes, DNA-binding proteins, and DNA sequence modulate retroviral integration target site selection. Cell 1992, 69, 769-780.
68. Bor, Y. C.; Miller,M. D.; Bushman, F. D.; Orgel, L. E. Targetsequence preferences of HIV-1 integration complexes in vitro. Virology 1996, 222, 283-288.
69. Katz, R. A.; DiCandeloro, P.; Kukolj, G.; Skalka, A. M. Role of DNA end distortion in catalysis by avian sarcoma virus integrase. J. Biol. Chem. 2001, 276, 34213-34220.
70. Pruss, D.; Bushman, F. D.; Wolffe, A. P. Human immunodeficiency virus integrase directs integration to sites of severe DNA distortion within the nucleosome core. Proc. Natl. Acad. Sci. USA 1994, 91, 5913-5917.
71. Pruss, D.; Reeves, R.; Bushman, F. D.; Wolffe, A. P. The influence of DNA and nucleosome structure on integration events directed by HIV integrase. J. Biol. Chem. 1994, 269, 25031-25041.
72. Leitner, T.; Foley, B.; Hahn, B.; Marx, P.; McCutchan, F.; Mellors, J.; Wolinsky, S.; Korber, B. HIV Sequence Compendium, Published by Theoretical Biology and Biophysics, Group T-10, Mail Stop K710, Los Alamos National Laboratory, Los Alamos, New Mexico 87545 (LA-UR-06-0680). 2005.
73. Leitner, T.; Foley, B.; Hahn, B.; Marx, P.; McCutchan, F.; Mellors, J.; Wolinsky, S.; Korber, B. HIV Sequence Compendium, Published by Theoretical Biology and Biophysics, Group T-10, Mail Stop K710, Los Alamos National Laboratory, Los Alamos, New Mexico 87545 (LA-UR-06-0680). 2005.
74. Wang, L. D.; Liu, C. L.; Chen, W. Z.; Wang, C. X. Constructing HIV-1 integrase tetramer and exploring influences of metal ions on forming integrase-DNA complex. Biochem. Biophys. Res. Commun. 2005, 337, 313-319.
75. Wijitkosoom, A.; Tonmunphean, S.; Truong, T. N.; Hannongbua, S. Structural and dynamical properties of a full-length HIV-1 integrase: Molecular dynamics simulations. J. Biomol. Struct. Dyn. 2006, 23, 613-624.
76. Ren, G.; Gao, K.; Bushman, F. D.; Yeager, M. Single-particle image reconstruction of a tetramer of HIV integrase bound to DNA. J. Mol. Biol. 2007, 366, 286-294.
77. Anker, M.; Corales, R. B. Raltegravir (MK-0518): A novel integrase inhibitor for the treatment of HIV infection. Expert Opin. Investig. Drugs 2008, 17, 97-103.
78. Sato, M.; Motomura, T.; Aramaki, H.; Matsuda, T.; Yamashita, M.; Ito, Y.; Kawakami, H.; Matsuzaki, Y.; Watanabe, W.; Yamataka, K.; Ikeda, S.; Kodama, E.; Matsuoka, M.; Shinkai, H. Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J. Med. Chem. 2006, 49, 1506-1508.
79. Barreca, M. L.; De Luca, L.; Iraci, N.; Chimirri, A. Binding mode prediction of strand transfer HIV-1 integrase inhibitors using Tn5 transposase as a plausible surrogate model for HIV-1 integrase. J. Med. Chem. 2006, 49, 3994-3997.
80. Ason, B.; Knauss, D. J.; Balke, A. M.; Merkel, G.; Skalka, A. M.; Reznikoff, W. S. Targeting Tn5 transposase identifies human immunodeficiency virus type 1 inhibitors. Antimicrob. Agents Chemother. 2005, 49, 2035-2043.
81. Jin, H.; Cai, R. Z.; Schacherer, L.; Jabri, S.; Tsiang, M.; Fardis, M.; Chen, X.; Chen, J. M.; Kim, C. U. Design, synthesis, and SAR studies of novel and highly active tricyclic HIV integrase inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 3989-3992.
82. Kawasuji, T.; Fuji, M.; Yoshinaga, T.; Sato, A.; Fujiwara, T.; Kiyama, R. A platform for designing HIV integrase inhibitors. Part 2: A two-metal binding model as a potential mechanism of HIV integrase inhibitors. Bioorg. Med. Chem. 2006, 14, 8420-8429.
83. Anti-HIV agents. New drugs-Hope and a degree of caution. TreatmentUpdate 2007, 19, 9-10.
84. Anti-HIV agents. Raltegravir (Isentress)-Results after one year. TreatmentUpdate 2007, 19, 8-9.
85. Iwamoto, M.; Wenning, L. A.; Petry, A. S.; Laethem, M.; De Smet, M.; Kost, J. T.; Merschman, S. A.; Strohmaier, K. M.; Ramael, S.; Lasseter, K. C.; Stone, J. A.; Gottesdiener, K. M.; Wagner, J. A. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin. Pharmacol. Ther. 2008, 83, 293-299.
86. Lodi, P. J.; Ernst, J. A.; Kuszewski, J.; Hickman, A. B.; Engelman, A.; Craigie, R.; Clore, G. M.; Gronenborn, A. M. Solution structure of the DNA binding domain of HIV-1 integrase. Biochemistry 1995, 34, 9826-9833.
87. Bujacz, G.; Jaskolski, M.; Alexandratos, J.; Wlodawer, A.; Merkel, G.; Katz, R. A.; Skalka, A. M. High-resolution structure of the catalytic domain of avian sarcoma virus integrase. J. Mol. Biol. 1995, 253, 333-346.
88. Bujacz, G.; Alexandratos, J.; Wlodawer, A.; Merkel, G.; Andrake, M.; Katz, R. A.; Skalka, A. M. Binding of different divalent cations to the active site of avian sarcoma virus integrase and their effects on enzymatic activity. J. Biol. Chem. 1997, 272, 18161-18168.
89. Dirac, A. M.; Kjems, J. Mapping DNA-binding sites of HIV-1 integrase by protein footprinting. Eur. J. Biochem. 2001, 268, 743-751.
90. Grobler, J. A.; Stillmock, K.; Hu, B.; Witmer, M.; Felock, P.; Espeseth, A. S.; Wolfe, A.; Egbertson, M.; Bourgeois, M.; Melamed, J.; Wai, J. S.; Young, S.; Vacca, J.; Hazuda, D. J. Diketo acid inhibitor mechanism and HIV-1 integrase: Implications for metal binding in the active site of phosphotransferase enzymes. Proc. Natl. Acad. Sci. USA 2002, 99, 6661-6666.
91. Davies, J. F., 2nd; Hostomska, Z.; Hostomsky, Z.; Jordan, S. R.; Matthews, D. A. Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase. Science 1991, 252, 88-95.
92. Steitz, T. A.; Steitz, J. A. A general two-metal-ion mechanism for catalytic RNA. Proc. Natl. Acad. Sci. USA 1993, 90, 6498-6502.
93. Brautigam, C. A.; Steitz, T. A. Structural and functional insights provided by crystal structures of DNA polymerases and their substrate complexes. Curr. Opin. Struct. Biol. 1998, 8, 54-63.
94. Eijkelenboom, A. P.; Sprangers, R.; Hard, K.; Puras Lutzke, R. A.; Plasterk, R. H.; Boelens, R.; Kaptein, R. Refined solution structure of the C-terminal DNA-binding domain of human immunovirus-1 integrase. Proteins 1999, 36, 556-564.
95. Gerton, J. L.; Ohgi, S.; Olsen, M.; DeRisi, J.; Brown, P. O. Effects of mutations in residues near the active site of human immunodeficiency virus type 1 integrase on specific enzymesubstrate interactions. J. Virol. 1998, 72, 5046-5055.
96. Bushman, F. D.; Fujiwara, T.; Craigie, R. Retroviral DNA integration directed by HIV integration protein in vitro. Science 1990, 249, 1555-1558.
97. Zheng, R.; Jenkins, T. M.; Craigie, R. Zinc folds the N-terminal domain of HIV-1 integrase, promotes multimerization, and enhances catalytic activity. Proc. Natl. Acad. Sci. USA 1996, 93, 13659-13664.
98. Jenkins, T. M.; Engelman, A.; Ghirlando, R.; Craigie, R. A soluble active mutant of HIV-1 integrase: Involvement of both the core and carboxyl-terminal domains in multimerization. J. Biol. Chem. 1996, 271, 7712-7718.
99. Andrake, M. D.; Skalka, A. M., Multimerization determinants reside in both the catalytic core and C terminus of avian sarcoma virus integrase. J. Biol. Chem. 1995, 270, 29299-29306.
100. Asante-Appiah, E.; Skalka, A. M. HIV-1 integrase: Structural organization, conformational changes, and catalysis. Adv. Virus Res. 1999, 52, 351-369.
101. Asante-Appiah, E.; Skalka, A. M. A metal-induced conformational change and activation of HIV-1 integrase. J. Biol. Chem. 1997, 272, 16196-16205.
102. Vink, C.; Lutzke, R. A.; Plasterk, R. H. Formation of a stable complex between the human immunodeficiency virus integrase protein and viral DNA. Nucleic Acids Res. 1994, 22, 4103-4110.
103. Lutzke, R. A.; Vink, C.; Plasterk, R. H. Characterization of the minimal DNA-binding domain of the HIV integrase protein. Nucleic Acids Res. 1994, 22, 4125-4131.
104. Sayasith, K.; Sauve, G.; Yelle, J. Characterization of mutant HIV-1 integrase carrying amino acid changes in the catalytic domain. Mol. Cells 2000, 10, 525-532.
105. Lu, R.; Limon, A.; Ghory, H. Z.; Engelman, A. Genetic analyses of DNA-binding mutants in the catalytic core domain of human immunodeficiency virus type 1 integrase. J. Virol. 2005, 79, 2493-2505.
106. Lutzke, R. A.; Plasterk, R. H. Structure-based mutational analysis of the C-terminal DNA-binding domain of human immunodeficiency virus type 1 integrase: Critical residues for protein oligomerization and DNA binding. J. Virol. 1998, 72, 4841-4848.
107. van Gent, D. C.; Groeneger, A. A.; Plasterk, R. H. Mutational analysis of the integrase protein of human immunodeficiency virus type 2. Proc. Natl. Acad. Sci. USA 1992, 89, 9598-9602.
108. Engelman, A.; Liu, Y.; Chen, H.; Farzan, M.; Dyda, F. Structure-based mutagenesis of the catalytic domain of human immunodeficiency virus type 1 integrase. J. Virol. 1997, 71, 3507-3514.
109. Harper, A. L.; Skinner, L. M.; Sudol, M.; Katzman, M. Use of patient-derived human immunodeficiency virus type 1 integrases to identify a protein residue that affects target site selection. J. Virol. 2001, 75, 7756-7762.
110. Engelman, A.; Bushman, F. D.; Craigie, R. Identification of discrete functional domains of HIV-1 integrase and their organization within an active multimeric complex. EMBO J. 1993, 12, 3269-3275.
111. Morgan, A. L.; Katzman, M. Subterminal viral DNA nucleotides as specific recognition signals for human immunodeficiency virus type 1 and visna virus integrases under magnesium-dependent conditions. J. Gen. Virol. 2000, 81, 839-849.
112. Katz, R. A.; Gravuer, K.; Skalka, A. M. A preferred target DNA structure for retroviral integrase in vitro. J. Biol. Chem. 1998, 273, 24190-24195.
113. Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, D. M.; Meng, E. C.; Ferrin, T. E. UCSF Chimera-A visualization system for exploratory research and analysis. J. Comput. Chem. 2004, 25, 1605-1612.
114. Maestro, version 8.0. Schrödinger, New York, 2007.